No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Instruments & Supplies
Bonesupport Holding AB (publ) is a specialized orthobiologics firm dedicated to the creation and global commercialization of injectable bioceramic bone graft substitutes, designed to effectively treat bone voids. Its innovative solutions are distributed across Europe, North America, and other international territories. The company's key offerings include CERAMENT Bone Void Filler, a synthetic, injectable material that is both moldable and drillable, formulated with hydroxyapatite, calcium sulfate, and the radiopaque agent iohexol. Furthermore, Bonesupport provides CERAMENT G, a ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Beyond its current product line, Bonesupport is actively engaged in preclinical research to develop novel candidates aimed at promoting bone regeneration. This research targets challenging conditions such as trauma, revision arthroplasty, chronic osteomyelitis, various oncological applications, and bone and foot infections often associated with diabetes. Established in 1999, the company is headquartered in Lund, Sweden.
www.bonesupport.comNo one on the platform currently holds 2B4.F.
No tracked institution reports a position in 2B4.F as of their last filing.
No one on the platform has traded 2B4.F yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 39.6% | — | — | — | ||
| Rev. Growth % | 30.7% | 45.4% | ||||
| Profit Margin % | 12.1% | 1.5% | -54.0% | |||
| Free Cash Flow Margin % | 18.6% | -7.0% | -54.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.5B | +24.6% | $4.87 | $4.70–$5.08 | — | 1 |
| 2027 | $1.9B | +32.2% | $7.31 | $7.05–$7.62 | — | 1 |
| 2028 | $2.4B | +26.1% | $9.98 | $9.61–$10.39 | — | 1 |
| 2029 | $2.8B | +15.8% | $12.11 | $11.68–$12.62 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-16 | $0.10 | $0.11 | +8.9% |
| 2026-04-22 | $0.09 | $0.07 | -16.6% |
| 2026-02-24 | $0.08 | $0.06 | -24.0% |
| 2025-10-23 | $0.07 | $0.05 | -35.3% |
| 2025-07-15 | $0.07 | $0.07 | +6.7% |
| +2.62% |
| $2.1B |
| — |
| EUZ.DEEckert & Ziegler SE | $12.35 | +0.41% | $773M | — |
| EVT.DEEvotec SE | $2.86 | -3.64% | $508M | — |
Source: Financial Modeling Prep · peers by sector/industry